论文部分内容阅读
目的:观察参芪复方对GK大鼠大血管病变主动脉环氧化酶(COX-2)mRNA表达的影响。方法:设GK组、模型组、阿托伐他汀组、参芪复方组及Wistar正常对照组,各组大鼠灌胃及喂饲相应药物或饲料35d。酶联免疫法检测血清C-反应蛋白(CRP),实时定量RT-PCR和免疫组织化学法分别检测主动脉的COX-2mRNA表达。结果:阿托伐他汀组、参芪复方组CRP水平明显低于模型组(P<0.01),阿托伐他汀组和参芪复方组模动物腹主动脉血管壁COX-2mRNA表达水平显著降低,且与模型组比较表达量水平均有显著性差异(P<0.01),阿托伐他汀组、参芪复方组间比较无差异。结论:参芪复方可以显著降低GK大鼠早期动脉粥样硬化形成模型血循环中CRP血清含量及炎性介质大动脉血管中的COX-2mRNA含量。COX-2可能也是参芪复方抗糖尿病炎症反应的靶点之一。
Objective: To observe the effect of Shenqi Compound on cyclooxygenase (COX-2) mRNA expression in aortic macroangiopathy in GK rats. Methods: GK group, model group, atorvastatin group, Shenqi compound group and Wistar normal control group were established. The rats in each group were fed with the corresponding drugs or feed for 35 days. Serum C-reactive protein (CRP) was detected by enzyme-linked immunosorbent assay. The expression of COX-2 mRNA in the aorta was detected by real-time quantitative RT-PCR and immunohistochemistry. Results: The levels of CRP in atorvastatin group and Shenqi Compound group were significantly lower than those in model group (P <0.01). The expression of COX-2 mRNA in abdominal aorta of atorvastatin group and Shenqi compound group was significantly decreased, Compared with the model group, the level of expression was significantly different (P <0.01). There was no difference between atorvastatin group and Shenqi compound group. Conclusion: Shenqi compound can significantly reduce the level of CRP in blood circulation and the expression of COX-2mRNA in inflammatory arteries in GK rats with early atherosclerosis formation. COX-2 may also be one of the targets of Shenqi compound anti-diabetic inflammation.